Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical
company focused on precision diagnostic radiopharmaceuticals, today
announced that Dr. Mark Pykett, VMD PhD, Navidea Chief Executive
Officer, and other members of Navidea management will participate in the
2014 Biotech Showcase Conference from January 13-15, 2014 held at the
Parc 55 Wyndham-Union Square in San Francisco, CA. Dr. Pykett will
provide an update of the Company and its commercial and development
programs on Monday, January 13, 2014 at 11:00 AM PST in the Powell Room.
Investors and the public are invited to listen to a live webcast of Dr.
Pykett's presentation at http://www.media-server.com/m/p/etqv5fpu.
Following the conference, the webcast will be archived for approximately
About Navidea Biopharmaceuticals, Inc.Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company
focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is developing
multiple precision diagnostic products and platforms including NAV4694,
NAV5001, Manocept™ and RIGScanTM, to help identify the sites
and pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making and, ultimately, patient care.
Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea's
first commercial product from the Manocept platform, was approved by the
FDA in March 2013. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company's pipeline through selective
acquisitions, global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
[ Back To NFVZone's Homepage ]